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Spinal Muscular Atrophy is a recessive genetic disease and affects lower motor neurones and muscle tissue. A single gene is
disrupted in SMA: SMN1 activity is abolished but a second copy of the gene (SMN2) provides limited activity. While the SMN
protein has been shown to function in the assembly of RNA-protein complexes, it is unclear how the overall reduction in SMN
activity specifically results in the neuromuscular phenotypes. Similar to humans, reduced smn activity in the fly causes earliest
phenotypes in neuromuscular tissues. To uncover the effects of reduced SMN activity, we have studied gene expression in
control and diseased fly tissues using whole genome micro-arrays. A number of gene expression changes are recovered and
independently validated. Identified genes show trends in their predicted function: several are consistent with the function of
SMN, in addition some uncover novel pathways. This and subsequent genetic analysis in the fly indicates some of the
identified genes could be taken for further studies as potential drug targets for SMA and other neuromuscular disorders.
Citation: Lee S, Sayin A, Grice S, Burdett H, Baban D, van den Heuvel M (2008) Genome-Wide Expression Analysis of a Spinal Muscular Atrophy Model:
Towards Discovery of New Drug Targets. PLoS ONE 3(1): e1404. doi:10.1371/journal.pone.0001404
INTRODUCTION
Whole genome expression analysis of animals and tissues offers a
novel way of penetrating functional changes in diseased versus
normal tissues. Such analysis will map direct and indirect effects of
the disease state on gene expression and could identify novel gene
targets for drug interference.
Genome wide expression arrays have been made possible by the
annotation and gene predictions of whole genome sequence data
for human and a large number of model organisms. The genome
sequencing work and subsequent species comparisons have also
indicated that the genetic differences between species are smaller
than anticipated. Both the total number of genes identified and,
interestingly, the variety of encoded proteins (and domains) are
smaller than expected. Combining these findings with functional
genetic analysis has led to the conclusion that for most tissues a
group of highly conserved genes is required for differentiation and
subsequent function. These genes are expressed and functional in
the investigated tissues across the evolutionary tree of animal
species. Tissue specific analysis can thus be performed in
analogous tissues using a wide variety of model organisms,
concentrating on these highly conserved genes.
We have decided to probe the function of known human disease
genes by creating and studying mutants in homologues of such
genes, in simple model organisms. Here we present a study of gene
expression in a simple model organism to identify novel gene
pathways that are differentially regulated in normal versus mutant,
i.e. diseased, states. The identification of such pathways could
potentially lead to the identification of novel drug targets.
SMA is a common recessive genetic disease affecting 1:8000-
10.000 across the human population and is characterized by a
specific loss of lower motor neurones and muscle atrophy. The
genetic cause was identified as the Survival Motor Neurone gene
(SMN), however, in the disease situation, SMN protein activity is
never completely lost, instead is reduced [1]. The human genome
contains two copies of the SMN gene, the activity of the first copy
(SMN1) is genetically affected in patients and they therefore rely
totally on the activity contributed by the second copy (SMN2).
However SMN2 produces less functional protein to varying degrees.
The level of remaining SMN activity has been directly correlated to
the severity of the phenotypes [2]. In the patient cohort this has lead
to distinct groupings, type I being strong, affecting newborns and
babies, type II, affecting childhood and type III, affecting late
childhood and adults; each group defined on the basis of concrete
motor abilities. The generation of an amenable model reflecting
human conditions has been complex. The mouse has a single SMN
gene and loss of the gene has been shown to lead to early embryonic
lethality[3].MolecularandfunctionaldatarelatingSMNfunctionto
SMAhavebeenslowtoaccumulateanddespitetheknowledgeofthe
genetic basis of the disease, little is known about the neuromuscular
background of the phenotypes.
The SMN gene is expressed ubiquitously in all animals
investigated [4]. Extensive biochemical analysis concluded that it
is involved in the assembly of large RNA-protein complexes, one
of which is the spliceosome (reviewed in [5,6]). Although this work
was critical in understanding the function of the SMN protein, it
doesn’t explain the neuronal and/or muscle specificity of SMA.
Thus it remains unclear why this protein seemingly required for
basal functions in the cell, leads to such specific phenotypes when
activity falls below a certain threshold. It is possible that a certain
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or SMN might perform a highly specific function in these tissues.
We have generated a fly model for SMA by knocking out the
endogenous smn gene. Unlike in mice, the knock-out animals are
born; the embryos survive on the basis of maternal contribution of
transcripts coding for normal Smn protein. Maternal contribution,
in the homozygous mutant background, runs out during larval
stages and leads primarily to neuromuscular phenotypes before the
animals die. Because the only genetic aberration in these animals is
the reduction of SMN activity, the observed phenotypes must be
due to SMN activity reaching a threshold for neuromuscular
functionality. Further characterisation showed that these larvae
develop clear external motor problems and cell and physiological
defects at the motor neuron-muscle junction [7].
To further the molecular understanding of SMA we used our fly
model in a genome wide gene expression analysis. We performed
micro array analysis of whole animals and SMA affected tissues
across normal and smn mutant animals. We used Drosophila whole
genome arrays and have produced statistically relevant results. We
have validated these using standard methods. In addition we find
that, using genetic testing in the fly to investigate functional
interactions, novel loci influencing the smn mutant phenotypes can
be identified using these data, thus opening the path for novel drug
target studies.
RESULTS
Experimental background
We set out to analyse gene expression in whole animals as well as
in individual tissues. The latter potentially poses a problem due to
the low quantities of starting material that can be obtained from
Drosophila. In order to assess gene expression using micro arrays
based on the high density GeneChip system, we needed to
establish if it was possible to obtain reliable expression data using
small quantities of Drosophila RNA.
We compared the same RNA sample at different dilutions, using
the ‘‘low starting material’’ amplification procedures to obtain
labelled cRNA for the low concentrations (see Material and
methods). The overall yield of labelled RNA and the quality of the
hybridisation data are presented in Supplemental Figure S1. Using
the Affymetrix two-cycle amplification method we are able to
produce $15 ug cRNA using starting amounts as low as 0.1 ng;
below this level the output drops significantly. The product size
decreases as smaller amounts of RNA are used, resulting in 59
truncation of the cRNAand thesubsequent lossindetection ofgenes
with probes directed towards the 59 end of the gene. On the basis of
these tests, we used between 10 ng to 100 ng of starting material in
our experiments to minimise 59 truncation of the cRNA transcripts.
Experimental set up
Our aim was to compare gene expression changes between normal
and smn mutant animals and tissues. The strong genetics of
Drosophila make it possible to use a ‘‘normal’’ background that is
genetically very close to the mutant, this genetic system is thus
highly appropriate for genomic analysis. In this study we used a
mutant allele of smn that was recombined onto an isogenised third
chromosome background (see Materials and methods); the smn
mutant animals or isolated tissues will be homozygous for this
allele. The control ‘‘normal’’ background was the same isogenised
chromosome in homozygous state, but without the smn mutation.
The other chromosomes are free to drift genetically in both
normal and smn mutant strains.
To obtain information on the time frame of molecular changes
in the smn mutant background and thus when to isolate our
samples, we have assessed the neuromuscular tissues in second and
third instar larval stages. Motility defects in the smn mutant
animals are first seen halfway between these stages and are
statistically significant by third instar. At this life stage, we have
previously reported that clustering of the neurotransmitter
receptor is disrupted at the neuromuscular junction (NMJ) [7].
Disruption of neurotransmitter receptor clustering has also been
reported in patient tissue [8] and in a recently described mouse
model [9]. On our time course, in early second instar larvae the
accumulation of clusters of the neurotransmitter receptor,
Glutamate receptor IIA (GluR IIA), is similar in mutant animals
compared to controls (Figure 1). By late second stage the number
and size of clusters in the mutant tissues changes compared to the
controls. By the time that the larvae display motility problems
(third instar) this difference is exacerbated, leaving very few
clusters in the mutant situation. These results argue that the loss of
motility in our animals is concomitant with or proceeded by a loss
of neurotransmitter receptor clustering at the NMJ after an
initially normal pattern. Thus molecular defects are visible from
late second instar and increase into third instar stage, note
however that even at mid-to-late third instar stage little tissue
degeneration is observed (unpublished and see [7]. We used
animals at the second and third instar stage for whole animal gene
expression analysis and concentrated on individual tissues at the
later stage only. The loss in neurotransmitter receptor clustering is
most clearly seen at the later stage and since this defect has been
shown in other model systems and patients, it would be most
interesting to explore in our experimental analysis.
For tissue samples, we dissected muscle tissue and motor neuron
cell bodies from mobility impaired third instar larvae. The ventral
abdominal muscles were obtained by filleting larvae and removing
gut, neurons and dorsal muscles, the ventral muscles were dissected
from the remaining cuticle. The cell bodies of the motor neurons are
found in the ventral ganglion as part of the brain structure in the
larvae; this tissue was dissected out. The whole larvae and tissue
samples were processed to generate labelled cRNA.
We used the GC-RMA (Robust Multi-array Analysis) method to
normalize the hybridisation results; this method uses the GC
content of the probes to reduce variance in the mismatch (control)
probe levels as spotted on the Affymetrix arrays [10].
Hybridisation results
We combined the results across the various samples to identify
overlapping changes in gene expression. Any overlap patterns would
allow trends to be uncovered. Common disruptions might point to
an affected function in SMN deprived tissues. We used a 1.5 fold
change in expression as cut-off in these comparisons and stringent
statistics. We compared the expression changes for brain and muscle
tissues to the whole animal data. If the role of SMN in SMA is linked
to a general function that SMN performs in all cells then a
transcriptional response to reduced activity might be seen in all cells
of the animal. Conversely, changes specific to either muscle and/or
brain might point to genes that influence the tissue specificity of
SMA (see Gene Pathway Changes paragraph). The number of genes
that change in these comparisons is shown in Table 1, and the genes
listed in supplemental Figure S2, S3, S4, S5, S6, S7, S8, S9 and S10.
The number of genes in common between the tissue and whole
animal samples is small; each tissue sample itself shows consistently
the largest number of gene expression changes (‘‘No change in
larvae’’ row). This might reflect the fact that the lowered levels of
smn activity specifically affect the neuromuscular tissues; gene
expression changes specific to these tissues could fall below the cut-
off levels in the whole animal samples. We have previously assessed
the sensitivity of the muscle and neuronal tissues in a genetic
Spinal Muscular Atrophy
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homozygous smn mutant background. As expected rescue was
almost 100% by ubiquitous expression of the transgene, however,
interestingly, significant rescue was also observed when the
transgene was expressed solely in muscle and neurons. These
results showed clearly that these specific tissues in the fly are more
sensitive to the levels of smn compared to the rest of the animal [7].
Although it is difficult to concentrate on individual genes at this
point, we will highlight some here. Across all samples, three genes
encoding cytochrome P450 domains are up-regulated as well as
two Glutathione S transferases. Interestingly two genes that
encode G-protein-coupled-receptor-like proteins, amenable drug
targets, with unknown function are uniformly up-regulated.
Amongst the genes that are down regulated, different family
members of Glutathione S transferase (CG6776) and cytochrome
P450 (or electron transport, CG4511) encoding genes are found.
Within the down-regulated genes in the muscle a gene that has
predicted RNA cap binding function is found (CG8023).
The larval samples were taken at two time points and this
enables us to investigate the changes in gene expression across
time. Many genes that have been annotated but not functionally
analysed are identified in this way. Within these, a trend is
recognizable towards a down-regulation of metabolic and
transporter activities. Some genes associated with immune
response are found up-regulated. In both brain and muscle
samples (and whole larvae) a gene annotated as N-methyl-D-
aspartate receptor associated protein is up-regulated, only at the
later stage. This might indicate a link with the reduced
accumulation of Glutamate Receptors at the mutant NMJs in
the mutant animals. A protein known to function in transcript
transport and translation control, spire, is up-regulated at the
earlier stage in muscle only.
When looking only at the tissues samples, it appears that there
are more genes showing expression changes in muscle than in
brain samples. The overlap between muscle and brain samples will
uncover gene expression changes specific to the neuromuscular
system. The lower rows in Table 1 show the number of genes
changing and the genes are listed in supplemental Figures S2, S3,
S4, S5, S6, S7, S8, S9 and S10. Within the down-regulated genes
two syntaxin encoding genes are identified. Interestingly, three
genes encoding small Heat Shock Proteins are down-regulated
especially in the muscle sample.
To further understand whether SMN is required specifically in
the neuromuscular tissues, we have assessed the expression of the
smn gene in these tissues versus the rest of the animal using both
our array data and Real-Time Polymerase Chain Reaction (RT-
PCR) analysis. This latter method compared the concentration of
the smn transcript in larval and adult tissues against non-changing
control genes. This analysis clearly shows that expression of smn is
higher in larval and adult neuromuscular tissues, with especially
high expresssion in the nervous system (Figure 2).
The molecular analysis of the NMJs in the smn mutant clearly
showed a deregulation of GluR protein accumulation (GluR IIA
subunits). Using our data, we assessed the changes in expression of
some of the GluR genes (Table 2). GluR IIA and IIB, for which
protein is found at the NMJ, are mildly down regulated in smn
mutant muscle. GluR III (also knows as IIC) is up-regulated in smn
mutant muscle and no change is seen for GluR IID. All have a p
value #0.05 of change between controls and smn mutant muscle in
a Welch t-test.
Figure 1. Confocal Scanning Fluorescent images of Drosophila neuromuscular junctions. A to C, early second instar larvae; D to F, late second
instar larvae and G to I, third instar larvae (mid stage). A, D and G, normal (+/+) larvae, B, C, E, F, H and I, smn mutant larvae (smn/smn). A, B, D, E, G and
H stained for Glutamate receptor subunit; C, F and I stained for a pre-synaptic marker (syntaxin). Comparing the accumulation of receptor clusters in
the normal tissue across time to the mutant tissues, it is clear that the mutant displays a reduced number of glutamate receptor clusters across time.
doi:10.1371/journal.pone.0001404.g001
Spinal Muscular Atrophy
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requires at least GluR III and one of either IIA or IIB (and possibly
other sub units) [11]. The significant up-regulation we observe for
GluR III might be a response of the animal to the reduction of
receptor activity at the NMJ. The reduction intranscripts for the IIA
subunit cannot explain the degree of loss of clustering we see at the
neuromuscular junction, arguing the problem in the SMN depleted
tissue is not primarily based on transcript reduction.
Validation of array results
To assess the validity of our hybridisation results we examined the
expression of a number of genes, randomly picked from our list, of
differentially expressed genes using Real Time Polymerase Chain
Reaction (RT-PCR) amplification. Strong correlation between
PCR expression data and micro array values was found (Figure 3).
All changes determined by RT-PCR were statistically significant in
a Student’s t-test (n=3 and 4 for whole larvae and muscle
respectively) and consistent with the direction of change reported
by the micro-array analysis.
Gene pathway changes
To explore functional changes within neuromuscular tissues we
used Gene Ontology (GO) analysis to identify molecular pathways
that were up- or down-regulated in smn mutant tissues versus
control. Figure 4A shows a selection of categories in muscle and
brain tissues where respectively $ 20% and $ 10% of genes per
category are changed with a P value of #0.05 (Supplemental
Figures S11 and S12 show the full list of GO terms in muscle and
brain tissues, up and down regulated).
We find GO terms associated with NMJ physiology and
locomotion down regulated in the brain tissue while terms
involving general and rRNA metabolism are up regulated. In
the muscle samples, terms associated with cellular transport and
degradation are down-regulated. In addition neurotransmitter
associated terms are down regulated.
Interestingly within the up-regulated genes in the muscle, very
clear clustering of terms associated with energy metabolism is
observed. Out of the highly significant terms (more than 50% of
genes in a selected class are changing) more than half are
associated with energy generation and mitochondrial activities.
The other very clear grouping that is found up-regulated in the
muscle is associated with RNA metabolism. RNA polymerase
activity, RNA helicase as well as tRNA synthesis are found
amongst the highly significant changes. The established function of
SMN in RNA metabolism makes this an interesting observation.
This possibly relates to the following. Comparing the muscle and
brain samples, the gene expression changes in the muscle are often
more significant and a considerable larger number of genes is
found changed in muscle versus brain. These observations indicate
that the effect of the reduction of SMN activity leads to a more
pronounced response in muscle than in brain.
To study the temporal response to low SMN activity in the
whole organism, we compared the GO terms in the 2
nd and 3
rd
instar samples (using 20% cut off per category). The results are
shown in Figure 4B (the full lists are shown in Supplemental
Figures S13 and 14). Most changes in GO terms replicate across
these samples, this strongly indicates that these reflect real
responses to a reduction in SMN. In the down-regulated genes
many terms fall into the category of metabolic, especially
carbohydrate, enzyme activities. This indicates that the animals
are possibly slowing their metabolic rate. Consistent with this we
have observed that the mutant animals become emaciated.
In the up-regulated genes, interestingly, moving from the earlier
time point to the later, terms associated with lytic activities are
identified. This might indicate that the muscle tissues are very
sensitive to the continued reduction in SMN activity and become
degenerative (although no obvious signs are present on the tissue
level).
Genetic interactions
Our experiments show that expression of certain genes changes
dramatically in smn depleted tissues. The function of SMN has
been shown to involve the assembly of RNA-protein complexes
[5,12]. Rather than direct influences of SMN on gene transcrip-
tion, the changes in gene expression we observe are therefore likely
to be indirect due to the reduction of SMN activity. Such changes
could be associated with an attempt within the tissues to maintain
normal activity in the presence of depleted SMN function. Genes
that are found up-regulated could perform a rescue function in the
tissue. Reversely the down regulation of certain genes could be
associated with the tissue reducing the activity of pathways that are
disadvantageous at low levels of SMN. Agonists and antagonists to
the function of these genes could aid the tissues in their struggle
against phenotypes caused by low levels of SMN.
To further understand our findings and progress them into a
functional realm we performed genetic experiments. We set out to
probe if we could identify direct genetic interactions of loci
corresponding to isolated genes, with smn. We combined an smn
Table 1. Table showing the number of gene expression
changes at cut-off of $1.5 fold, in common between tissues
indicated and larvae of different stages.
......................................................................
Table 1a Larvae/brain comparisons
2
nd instar larvae 3
rd instar larvae Brain No. genes
No change No change Up 436
Up No change Up 27
No change Up Up 55
Up Up Up 22
No change No change Down 334
Down No change Down 22
No change Down Down 13
Down Down Down 17
Table 1b Larvae/Muscle comparisons
2
nd instar larvae 3
rd instar larvae Muscle No. genes
No change No change Up 1184
Up No change Up 30
No change Up Up 98
Up Up Up 28
No change No change Down 1363
Down No change Down 63
No change Down Down 45
Down Down Down 30
Table 1c Brain/muscle comparisons
Brain Muscle No. genes
Up Up 217
Down Down 185
Table showing the number of gene expression changes at cut-off of $1.5 fold,
in common between tissues indicated and larvae of different stages. Both larval
stages, and gene expression changes at $1.5 fold that are not seen in larvae are
shown, as well as changes in common only between Brain and Muscle samples.
All changes have a p-value of #0.05 in a two-tailed two-sample Welch t-test.
doi:10.1371/journal.pone.0001404.t001
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PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1404heterozygous mutant background with either mutant backgrounds
(where available) and/or with over-expression constructs of
random genes out of our lists. The selection of loci from our lists
was random except for the fact that we were limited by the
availability of genetic aberrations for selected genes. Table 3 shows
the genes selected and the results of these genetic tests.
The test we used relies on subtle changes in the survival of the
offspring. This test is relevant to the patient situation but it is only
partially probing any functional interaction. On the other hand we
examined a significant number of individuals in our test,
generating a statistically more relevant outcome. We could also
not assess if the aberrations we used here actually disrupt (or
enhance) the activity of the indicated gene (note that numbered
genes are only annotated as a gene and there are no functional
data).
Despite these calculated set-backs, we clearly identified some
genetic interactions with SMN in these tests and these will be
discussed below.
Figure 2. Smn gene expression analysis using two different methods. A) Results of micro-array hybridisations. ‘‘Sample’’ column lists the different
RNA samples used for cRNA preparation. The control and smn mutant relative concentrations are shown. Expression is low in the RNA samples
derived from whole animals but is significantly higher in neuromuscular tissues, especially in brain. The expression is reduced by 1.9 and 1.5 fold in
the mutant animals in muscle and brain respectively. Note that these tissues are mutant for the somatic gene (a point mutation so transcripts will be
produced) while still containing detectable maternal RNA (data not shown). B) Real Time-PCR analysis of smn expression across different tissues. The
Bar figure shows the relative abundance of smn transcript in tissues versus either whole animals (thus containing the isolated tissues; all third instar
larval stage derived) or versus isolated gut tissue (all adult derived), all from smn +/+. In both Central Nervous System (CNS) and muscle the
expression of smn is higher. C) The significance of this finding increases in adults
doi:10.1371/journal.pone.0001404.g002
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Here we present a study of genome-wide transcription changes in a
fly SMA model. Weshow that the technical difficulties inmicroarray
experiments of working with small amounts of tissue material,
inherent to working with Drosophila, aresurmountable.This has led
to statistically relevant and high quality data, which we indepen-
dently verified using direct transcript level measurements.
By comparing the transcriptome from whole animal and
individual tissues, samples isolated from virtually identical animals,
we show that across the animal metabolic changes are taking place
when SMN function is depleted. Across time, concomitant with the
advent of SMA-like defects, certain metabolic genes are down-
regulated.Interestingly,usingGeneOntologyanalysis,anotherset of
genes that are associated with metabolic processes is identified in the
muscle. These terms are mostly up-regulated and include many
mitochondrion localized processes. It appears that the depletion of
SMN function leads to metabolic changes in the animal.
Small Hsp genes provide activity to rescue cells under duress
and three such genes are isolated in muscle and brain tissues as
significantly changing in our experiments. Recently two such genes
have been pinpointed as leading to a form of Charcot-Marie-
Tooth disease, the most common inherited neuromuscular disease
[13,14]. These findings hint at a close and perhaps general
interaction of small HSP genes with neuromuscular disorders.
We have previously shown [7] that the accumulation of
neurotransmitter receptor at the SMN-depleted fly neuromuscular
junction is disrupted. Here we show that this is a temporal process,
while at the same time the levels of smn mRNA are slowly depleted.
Our current experiments show that the transcription of a rate-
limiting receptor subunit is increased, possibly reflecting an
adjustment made in gene expression to increase receptor complex
levels. In addition, our results also show for the first time, by using
array results and direct measurements, that the levels of smn mRNA
are higher in neuromuscular tissues, consistent with the higher
sensitivity of these tissues to SMN depletion. Interestingly,
comparing the reduction in GluR protein clusters with the reduction
of subunit transcripts, it appears that the clustering problem is not
based at the overall level of transcript. The suggested role of SMN in
transcriptlocalisation [15]thusindicatesthat SMNcouldactdirectly
on transcripts associated with neurotransmitter function.
The Gene Ontology analysis allows the identification of
functions affected in the system under study, rather than individual
genes. It is clear the energy metabolism is isolated as affected in
both types of analysis. In the muscle tissues metabolic processes
associated with the mitochondrion are strongly affected. In
amyotropic lateral sclerosis the case for an involvement of
mitochondrial disturbances, a fatal neurodegenerative disorder,
has been made extensively [16].
A second grouping of GO terms becomes obvious in the MAPP
Finder results. These are mostly associated with neurotransmitter
generation, levels and reception, as such involved in synaptic
function. In brain tissue, many of the GO terms identified fall within
this class, and they both increase as well as decrease in expression
levels. In muscle however, the situation is skewed towards genes that
aredecreasedinexpression.Theseresultspointtowardsafunctionof
SMN in the maintenance of synaptic function as driven by
neurotransmitter generation, transfer and reception. As mentioned
above, we have previously identified the loss of neurotransmitter
receptor clusters as a highly consistent and relatively early defect in
the smn mutant larvae. Clustering of receptors is at least partially
driven by pre-synaptic activity [17] and maintenance of clustering
has been shown to be dependent on glutamate (neurotransmitter at
the fly neuromuscular junction) [18]. These results indicate that
neurotransmitter metabolism might be a primary defect in the smn
mutant and thus in SMA pathology.
Drosophila is a popular model system because of its traceable
and rapid genetics. These qualities allow the discovery and
characterisation of hitherto unknown functional relations between
genes. We have used fly genetics to find new genes interacting with
SMN, by selecting loci from our array results and combining these
in a simple assay with the smn mutant locus in the fly. The number
of genes (and available mutations) does not allow for an extensive
study, however even in our limited analysis we have found
evidence for genetic interaction with some genes.
Because of the large number of genes representing metabolic
functions, our genetic analysis contains several of these. Interestingly
however all loci that appear positive in our test (Bc (Black cells), Lag1,
Aldh (Aldehyde dehydrogenase), stc (shuttle craft), und (uninitiated)a n d
bowl (brother of odd with entrails limited) are in some way functionally
associated with basic metabolism. Some are transcription oriented
some are associated with basic enzymatic functions. We would
conclude that although our test sample was small that metabolism is
an important factor in determining the overall survival of the smn
mutant animals and therefore possibly of SMA patients. On a more
general level, we feel that this type of analysis, combining genomic
technology with genetics will be useful in the functional analysis of
(human disease) genes in simple model organisms. In addition, the
continuous and rapid increase in molecularly characterised
mutations in random genes in the fly, will make the resources
reported here useful for further SMA functional studies.
MATERIALS AND METHODS
Fly strain used
Our lab had obtained a mutant in the smn gene by analyzing
candidate recessive-lethal mutants in the region where the gene is
located based on genome annotation (73A7-9) [7]. Sequence
analysis showed that one of the many lethal mutations in this
region, the mutant l(3) 73Ao, contained a point mutation in the
coding region of smn, resulting in a mis-sense mutation. Our lab
recombined this smn
73Ao mutant background with an isogenized
stock to remove any unwanted lethal mutations in the genetic
background (on the same chromosome). The resulting smn
73Ao
mutant was homozygous lethal at third larval stages.
The (normal) control used is the isogenic background on which
the smn mutant background was recombined.
Both lines were maintained using standard conditions. For
collection of material, flies were housed on apple juice plates with
yeast in 25uC incubator with 10 hrs light-14 hrs dark cycle. Times
larvae were isolated using genetic markers or Green Fluorescent
Protein (expressed on the non-mutant allele, homozygous mutants
will not light up green).
Table 2. Fold changes of GluR genes in smn mutant muscle
compared to wild type muscle (p value #0.05 of a difference
between the 2 conditions).
......................................................................
Glutamate receptor Affymetrix probe ID Fold change
IIA 143498_at 22.35
IIB 143926_at 21.82
III (IIC) 152969_at 4.3
IID 150272_at no change
Fold changes of GluR genes in smn mutant muscle compared to wild type
muscle (p value #0.05 of a difference between the 2 conditions). The GluR IID
gene is also known as KaiRIA.
doi:10.1371/journal.pone.0001404.t002
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For detection of specific proteins at the neuromuscular junction,
we used antibodies against Smn protein (described in Thomas et
al., under consideration) and syntaxin (see acknowledgements) on
dissected tissues (as above) fixed using 4% paraformaldehyde.
Incubations of antibodies (including secondary detection antibod-
ies obtained from Molecular Probes/Invitrogen) were done in
16PBS+0.1% Tween 20 and 0.3% saponin.
Sample collection
In total we collected four samples for RNA isolation. The first
sample is 2
nd instar larvae, second sample is 3
rd instar larvae. We
selected female larvae (on basis of externally visible markers for 3
rd
instar, for 2
nd instar we took 10 larvae total) in order to avoid any
sex related gene expression changes between samples. The larvae
were rinsed twice in 1xPBS (to wash off any bacteria or yeast)
before RNA preparation (see below). The third and fourth samples
Figure 3. Bar graphs showing the gene expression changes across a set of eight genes comparing Affymetrix micro-array hybridisation (top)
and Real-Time Polymerase Chain Reaction (bottom) results in whole 3rd instar larvae and muscle. Sample size was three for larvae and four for
muscle. The eight genes were CG6776, CG8836, Cyp4ac3, mthl3, Gip, CG4778, CG4511 and Tsp42Ed. The changes measured this way showed that
mRNA synthesis in whole 3rd instar SMN mutant larvae compared to WT larvae for CG6776 was decreased 3.57 fold (P,0.01), CG8836 was increased
14.6 fold (P,0.05), Cyp4ac3 was increased 2.7 fold (P,0.05), mthl3 was increased 8.9 fold (P,0.05). mRNA synthesis in SMN mutant larval muscle for
Gip was decreased 2.7 fold (P,0.01), CG4778 was decreased 2.7 fold (,P0.01), CG4511 was decreased 1.6 fold (P,0.05), Tsp42Ed was increased 21.6
fold (P,0.05) . The RT-PCR analysis validates the micro-array data: the overall directions of change are all identical and the fold changes are within the
same range
doi:10.1371/journal.pone.0001404.g003
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rd instar female larval brains and (abdominal ventral)
muscle. Both tissues were dissected from the larvae in 1xPBS, and
stored in RNAlater RNA Stabilization Reagent at 280uC. . Three
biological replicates of larvae were prepared and four biological
replicates of brain and muscle.
RNA preparation
Total RNA was extracted from 2
nd and 3
rd instar larvae using the
Qiagen RNeasy Mini Kit. The animals were homogenized in
350 mL RLT buffer (+ß-Mercapto-Ethanol: ME) with a hand held
homogenizer (5 mm probe blades) and the manufacturers protocol
was followed for further isolation.
Total RNA was extracted from brain and muscle tissues using
the Qiagen RNeasy Micro Kit, as above.
RNA concentration and integrity were assessed by absorbance
at 260 and 280 nm and by an Agilent Bioanalyzer RNA 6000
Nano Assay (data not shown).
Sample labelling and hybridisation to Affymetrix
array
Samples were prepared for Affymetrix analysis from whole 2
nd and
3
rd instar larvae using 1 ug starting RNA. The Affymetrix One-
Cycle Target Labelling and Control kit (P/N900493) was used
according to protocol 701027 Rev. 4 in the Affymetrix Eukaryotic
Sample and Array Processing Manual. For Drosophila larval brain
and muscle 100 ng and 40 ng starting RNA were used respectively.
To successfully generate sufficient labelled cRNA for microarray
analysis two rounds of amplification were necessary. For this the
Affymetrix Two-Cycle Target Labelling and Control kit was used
(P/N900494)according tothe manufacturer’sinstructionsdescribed
in the Affymetrix Eukaryotic Sample and Array Processing Manual
version 701027 Rev.5. For the first cycle of in vitro transcription the
Ambion MEGAscript T7 kit (P/N 1334) was used as detailed in the
Affymetrix manual. Labelled cRNA was hybridised to Drosophila 1
chipsandarrayswerewashedand thenscannedusingthe Affymetrix
GeneChip Scanner3000.
Analysis of differential gene expression
Microarray data were GCRMA normalised independently for
each tissue using GeneSpring GX (Agilent). Differentially
expressed genes were identified using a Welch t test with a p
value cut off of #0.05 and a fold change difference between wild
type and mutant smn of $1.5.
Real-Time RT-PCR (SYBR green)
Total RNA from WT and smn mutant whole 3
rd instar larvae and
muscle was used as a template for RT-PCR to independently
assess the validity of Affymetrix GeneChip data. 10 ng 3
rd instar
total larval RNA and 1 ng larval muscle RNA per sample was
used to synthesise first-strand cDNA, using random hexamers and
SuperScript III reverse transcriptase (Invitrogen). The cDNA was
used for quantitative real-time polymerase chain reaction (PCR)
amplification with Sybr Green chemistry (Applied Biosystems).
Primer Express software (Applied Biosystems) was used to design
Figure 4. A) A selection of Gene Ontology terms associated with up (red)- or down (green) -regulated genes in muscle and brain tissues,
comparing normal with smn mutant. B) A selection of Gene Ontology terms associated with up- or down-regulated genes in 2
nd and 3
rd instar
larvae, comparing normal with smn mutant, same colour-coding. For both A) and B) full lists of these terms are shown in Supplemental Figure S3.
doi:10.1371/journal.pone.0001404.g004
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RefSeq numbers and primer sequences are shown in Table 4.
Triplicate cDNA template samples were amplified and analyzed in
the Prism 7000 sequence detection system (Applied Biosystems).
The thermal cycle conditions were 50uC for 2 min, 95uC for
10 min, 40 cycles of 15 s at 95uC followed by 1 min at 60uC.
Immediately after the amplification, melt curve protocols were
performed to ensure that primer-dimers and other non-specific
products had been minimized or eliminated. A standard curve of
cycle thresholds using serial dilutions of cDNA samples was
established and used to calculate the relative abundance of the
target gene in WT and mutant smn samples. Values were
normalized to gamma-Tubulin (at map position 23C), we used
this gene as its expression was not changing in our Affymetrix
data. Minus RT samples tested simultaneously with experi-
mental samples by quantitative RT-PCR with Sybr Green
consistently yielded no amplification below 30 cycles using the
above protocol.
Real-time RT-PCR (Probe)
Real-time quantitative PCR was performed by using TaqMan
TAMRA probe chemistry on the ABI Prism 7000 Sequence
Detector System (Applied Biosystems). Primers and probes were
designed using Primer Express V2.0 software. Thermal Cycling
parameters were 95uC for 10 min, followed by 40 cycles of 95uC
for 1 minute, 59uC for 1 minute, and 72uC for 45 s. Aliquots of
50 ml consisting of primers, probes, cDNA and TaqMAN RT
PCR master mix were run in triplicate on the Applied Biosystems
7000 sequence detection system. Primers were used at 900 nM
concentration and probes at 20 nM concentration for both target
and control. A serial dilution for each target gene was run on each
plate in triplicate. The dilution series consisted of cDNA at 2 ng
1 ng, 0.5 ng 0.2 ng, 0.1 ng, 0.05 ng, and 0.02 ng concentrations.
Data was analysed using the comparative relative quantification
method and samples were normalised to both Actin42A and
GAPDH. Three plates were run for this experiment.
Table 3. Results of genetic experiments where smn mutant
allele and alleles named in 2
nd column were combined in
trans-heterozygous combination and welfare and survival
were tested by counting the number of individuals of each
genotype.
......................................................................
Gene/Down-regulated Putative Disruption used Result
l(2)k09913 BL12194 negative
CG5630 BL13026 negative
Zw BL4153 negative
CG1941 BL10535 negative
CG17838 BL10721 negative
Pgd BL11970 negative
l(1)G0320 BL11970 negative
CG1041 BL17954 negative
Bc BL12276 negative
Lag1 BL12276 weak
CG3823 BL16489 negative
CG7115 BL14190 negative
Aldh-III BL11342 very weak
CG12730 BL13004 negative
CG6028 BL14000 negative
Gene/Up-regulated
GstE7 BL17923 negative
mthl3 BL5574 negative
CG12505 BL12770 negative
CPTI BL13731 negative
CG6214 BL14544 negative
ab BL10520 unclear
CG1882 BL13732 negative
Hmgs BL11469 negative
stc BL11408 very weak
kraken BL13284 negative
CalpA BL13868 negative
Rbp9 BL12836 negative
Hlc BL4731 unclear
pelo BL11757 negative
CG7461 BL18095 negative
CG11107 BL12911 unclear
und BL6297 very weak
bowl BL7094 weak
h BL5529 negative
LK6 BL14934 negative
Results of genetic experiments where smn mutant allele and alleles named in
2
nd column were combined in trans-heterozygous combination and welfare
and survival were tested by counting the number of individuals of each
genotype. A positive score would be an outcome of more than 10% less
individuals of the trans-heterozygous background compared to the normal
alleles. Loci listed as negative did not show any genetic interaction in this test.
The genes mentioned in column one are abbreviated and/or annotation or full
names can be found on http://flybase.bio.indiana.edu/. On average more than
250 offspring were counted.
doi:10.1371/journal.pone.0001404.t003
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Table 4. Probe and Primer Sequences for Real-Time PCR
......................................................................
mRNA Sequence (59-39)
Accession
number
Tubulin 23C Forward AGTGCGGCAATCAAATTGG NM_057456
Reverse GCTCCAGGCACAATCTTTTCC
Mthl3 Forward GAAAGTGAAGAAGGAAGCACAAAAC NM_145335
Reverse GGACAAGCCCATGATGATAAAGA
CG6776 Forward CGGGCACAGGACAAGATTCT NM_139977
Reverse TGCCCTGCACAAGGATGTT
CG4511 Forward AGAAGCAGGAGTGGCTCAGAAA NM_141769
Reverse AAACAATGTTGGGCGACTTTTT
Tsp42Ed Forward GCGGCGTTTTTGTGAAATATG NM_078906
Reverse TGATGGAGCCGAAGGTGATAA
CG8836 Forward AGCGGGCTCCTATTCCTACAA NM_136929
Reverse CTGCTGCTGGTTTCCAATGTT
Cyp4ac3 Forward GCCATGCTGGACACTCTTTTG NM_135074
Reverse GGTATCGTATCCCCCGAACAT
CG4778 Forward CCCTACAACATTGACTGCATGAA NM_135495
Reverse GGCTTCTCGTGGCCAAAGT
Gip Forward CGATAGCCTTAGAGCCAGTAAAATG NM078551
Reverse ATTCCAGCGGCTTTGGAGTAT
doi:10.1371/journal.pone.0001404.t004
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Figure S1 cRNA yields and quality from decreasing amounts of
starting RNA. A) The yield of cRNA falls steeply when the amount
of starting material goes below 1 ng. B) The size distribution is
smaller when the 2 cycle labelling kit is used for 100 ng RNA
compared with cRNA transcripts generated using the 1 cycle kit
for 5 ug starting RNA. The smaller the amount of starting RNA
the smaller the transcripts that are generated. C) Scatter plots
show some genes decrease in signal when smaller amounts starting
amounts of RNA are used. This was shown to be due to 59
truncation of cRNA transcripts, preventing complete hybridisation
to the rarer 59 probe sets (data not shown). However the loss of
gene expression signal resulting from reduced starting material
may not always translate into changed gene expression changes.
Found at: doi:10.1371/journal.pone.0001404.s001 (0.70 MB
DOC)
Figure S2 Genes identified in brain tissue, not in 2nd and 3rd
instar larvae, corresponding to 1st and 5th rows in Table 1a.
Found at: doi:10.1371/journal.pone.0001404.s002 (0.09 MB
XLS)
Figure S3 Genes identified in 2nd instar larvae and brain tissue,
not in 3rd instar larvae, corresponding to 2nd and 6th rows in
Table 1a.
Found at: doi:10.1371/journal.pone.0001404.s003 (0.02 MB
XLS)
Figure S4 Genes identified in 3rd instar larvae and brain, not in
2nd instar larvae, corresponding to 3rd and 7th rows Table 1a.
Found at: doi:10.1371/journal.pone.0001404.s004 (0.02 MB
XLS)
Figure S5 Genes identified in brain, 2nd and 3rd instar larvae,
corresponding to 4th and 8th rows in Table 1a
Found at: doi:10.1371/journal.pone.0001404.s005 (0.02 MB
XLS)
Figure S6 Genes identified in muscle tissue, not in 2nd and 3rd
instar larvae, corresponding to 1st and 5th rows in Table 1b.
Found at: doi:10.1371/journal.pone.0001404.s006 (0.26 MB
XLS)
Figure S7 Genes identified in 2nd instar larvae and muscle
tissue, not in 3rd instar larvae, corresponding to 2nd and 6th rows
in Table 1b.
Found at: doi:10.1371/journal.pone.0001404.s007 (0.02 MB
XLS)
Figure S8 Genes identified in 3rd instar larvae and muscle, not
in 2nd instar larvae, corresponding to 3rd and 7th rows in
Table 1b.
Found at: doi:10.1371/journal.pone.0001404.s008 (0.03 MB
XLS)
Figure S9 Genes identified in muscle, 2nd and 3rd instar larvae,
corresponding to 4th and 8th rows in Table 1b
Found at: doi:10.1371/journal.pone.0001404.s009 (0.02 MB
XLS)
Figure S10 Genes identified as in common between brain and
muscle samples, corresponding to last two rows in Table 1c.
Found at: doi:10.1371/journal.pone.0001404.s010 (0.06 MB
XLS)
Figure S11 Gene Ontology (GO) collective terms for genes that
are differentially regulated in SMN mutant muscle with a 1.5 fold
cut-off. Terms are selected only if 20% or more of genes in a GO
term are changed.
Found at: doi:10.1371/journal.pone.0001404.s011 (0.08 MB
XLS)
Figure S12 Gene Ontology (GO) collective terms for genes that
are differentially regulated in mutant SMN brain with a 1.5 fold
cut-off. GO terms are selected only if 10% or more of genes in a
GO term are changed.
Found at: doi:10.1371/journal.pone.0001404.s012 (0.03 MB PPT)
Figure S13 Gene Ontology (GO) collective terms for genes that
are differentially regulated in SMN mutant 2nd instar larvae with
a 1.5 fold cut-off. Terms are selected only if 20% or more of genes
in a GO term are changed
Found at: doi:10.1371/journal.pone.0001404.s013 (0.02 MB
XLS)
Figure S14 Gene Ontology (GO) collective terms for genes that
are differentially regulated in SMN mutant 3rd instar larvae with a
1.5 fold cut-off. Terms are selected only if 20% or more of genes in
a GO term are changed
Found at: doi:10.1371/journal.pone.0001404.s014 (0.02 MB
XLS)
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